(AOF) – Carmat, designer and developer of the most advanced total artificial heart in the world, today announces a conditional agreement in principle with the European Investment Bank (EIB) on the terms of repayment of the loan taken out in December 2018 with of the latter to extend its maturity and limit the cash flows associated with its repayment.
The agreement in principle covers all three tranches of the loan and would allow Carmat, if implemented, to avoid having to repay this loan before July 31, 2026.
As a reminder, the first tranche of the loan (for a total amount of around 15 million euros in principal and interest) was initially due on January 31, 2024, and the second and third tranches in 2025 and 2026 respectively. .
Taking into account this agreement and its cash position, the company can finance its activities, according to its current “business plan” until the end of January 2024.
Carmat estimates its financing needs at around 50 million euros until the end of 20244. The Company therefore continues to work very actively on other initiatives to, in the very short term, strengthen its equity and alleviate its cash flow constraints. , and thus be able to continue its activities beyond the end of January 2024.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.